According to the latest report by IMARC Group, titled “Inhaled Nitric Oxide Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, The global inhaled nitric oxide market size reached US$ 877.0 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,361.1 Million by 2028, exhibiting a growth rate (CAGR) of 7.8% during 2023-2028.

Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that skilled doctors supervise at tertiary neonatal intensive care units (NICUs). It aids in regulating vascular muscle tone and treating hypoxemic respiratory failure among newborn children by enhancing ventilation-perfusion mismatch and minimizing hypertension and elevated pulmonary vascular resistance. Inhaled nitric oxide also assists in decreasing the need for extracorporeal membrane oxygenation (ECMO) and improving oxygenation. Currently, iNO therapy is being increasingly used as a rescue agent for acute respiratory distress syndrome (ARDS) patients.

Inhaled Nitric Oxide Market Trends:

The rising prevalence of various respiratory and other subsequent diseases in newborns, including persistent pulmonary hypertension and neonatal hypoxic respiratory failure (HRF), is driving the inhaled nitric oxide market. Furthermore, the growing geriatric population, who are more prone to atherosclerosis, hypertension, peripheral artery disease, thrombosis, etc., is also augmenting the product demand. Moreover, iNO is gaining immense traction for the treatment of chronic obstructive pulmonary disease (COPD), ARDS, asthma, etc. Additionally, iNO therapy is also being used against coronavirus stains as it helps in improving ventilation/perfusion in patients with severe pneumonia. Besides this, the ongoing research and development (R&D) activities in the healthcare industry are anticipated to bolster the market growth in the coming years.

Request Free Sample Report: https://www.imarcgroup.com/inhaled-nitric-oxide-market/requestsample

Global Inhaled Nitric Oxide Market 2023-2028 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

  • Air Liquide S.A
  • Bellerophon Therapeutics
  • Beyond Air Inc.
  • Linde plc
  • Mallinckrodt plc
  • Merck KGaA
  • Novoteris LLC
  • Nu-Med Plus
  • VERO Biotech LLC.

The report has segmented the market on the basis on region and application.

Breakup by Application:

  • Neonatal Respiratory Treatment
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Acute Respiratory Distress Syndrome (ARDS)
  • Others

Breakup by Region:

  • North America:( United States, Canada)
  • Asia-Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico,Others)
  • Middle East and Africa

Key highlights of the report:

  • Market Performance (2017-2022)
  • Market Outlook (2023- 2028)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=4100&flag=C

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA 
Follow us on Twitter: @imarcglobal
Linkedin: https://www.linkedin.com/company/imarc-group